Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Frankincense Tested as Possible Breast, Colon Cancer Treatment

By Medical University of South Carolina | October 11, 2017

Cancer surgeon and researcher Nancy DeMore is leading a clinical trial using frankincense to try to treat breast and colon cancer at the Medical University of South Carolina. The study was inspired by a research specialist in DeMore’s lab.

Ingrid Bonilla had researched frankincense as a treatment on breast cancer cells as an undergraduate student at Charleston Southern University. “Seeing encouraging results in our lab, I did my research on clinical studies with frankincense. I contacted the author of the only published breast cancer clinical case study to find out more.”

DeMore, who has done extensive research on new treatments for breast cancer, was willing to put it to the test. “It’s nice to see doctors like her who think outside the box,” Bonilla says. “Out of all the physicians that I talked to about this, Dr. DeMore was the only one who was interested in moving this forward.”

DeMore says boswellic acid, the extract from Indian frankincense, may help patients by reducing inflammation. The chemical structure of boswellic acid is similar to other anti-inflammatory drugs such as ibuprofen. Bonilla and DeMore wrote the current clinical trial with data from clinical trials of the extract in Europe.

DeMore says their study is “window of opportunity” trial that takes advantage of the window of time between the initial diagnosis of breast or colon cancer and surgery to remove the cancer. The patient will take boswellia while waiting for surgery.

“Tumor from the biopsy that was taken to make the diagnosis of cancer before treatment will be is compared to the tumor taken at surgery after treatment,” DeMore said. “This will allow us to assess whether taking boswellia changes the biology of the tumor.”

Frankincense would not be the only plant-based treatment for illness. For example, digoxin, from the foxglove plant, is used to treat cardiac arrhythmias. DeMore says it’s important to put potential treatments through rigorous testing. “A lot of herbs and alternative therapies haven’t been studied scientifically, so it’s really important to know, in a well-designed clinical trial, these natural products work.”

DeMore started her research into natural products with curcumin in the 1990s. Extracted from turmeric, curcumin inhibits blood vessel growth in tumors. Slowing the growth of new blood vessels in tumors is a common approach to treating many cancers.

DeMore then set out to test medicinal uses of other natural products. “What we are really committed to doing is to study natural products in a well-designed clinical trial to prove whether or not there is a benefit. We don’t know if it’s going to work.”

The MUSC Hollings Cancer Center is funding the trial.

While the preclinical evidence for boswellic acid seems promising, it’s important not to replace standard treatment with natural therapies that haven’t been studied well, Demore says. “The traditional treatments that we advise for patients have been through extensive, rigorous clinical trials where the benefits of treatment are well-known, as are the side effects.”

She says therapies that aren’t based on clinical trial results could have unexpected side effects, or even harmful effects. She also says people should be aware that over-the-counter frankincense may not contain the dosage or quality of the extract being tested in this study.

Bonilla is just grateful that DeMore took her idea seriously. “Sometimes I’m, like, ‘Wow! I never pictured myself five years ago sitting here and being involved in anything like this.’ I consider myself very blessed,” she says.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE